GlobeNewswire

GLOBAL SCRUM GATHERING KICKS OFF OCTOBER 30 IN DUBLIN

Dela

SCRUM ALLIANCE HOSTS GLOBAL GATHERING WITH MORE THAN 600 ATTENDEES

MEDIA CONTACT:

Heather Leigh

Public Relations & Communications Director

720-443-7314, hleigh@scrumalliance.org


DENVER, CO, and DUBLIN, IRELAND - Scrum Alliance®, the largest, most established and influential professional membership organization and certifying body in the Agile community, announced that its Global Scrum Gathering® in Dublin kicks off October 30. More than 600 people from around the world will be attending this event, which offers business leaders, managers, corporations, and practitioners worldwide the opportunity to share their passion for and knowledge of Agile and Scrum practices that are transforming the world of work.

"We are thrilled to be in Dublin, Ireland, for our 2017 European Global Gathering," said Lisa W. Hershman, Scrum Alliance interim CEO. "It's an exciting time to discuss Agile transformation in Ireland, with Irish businesses predicted to invest in digital transformation on a grand scale over the next year. We can't wait to demonstrate and discuss how our community in Europe has been implementing Scrum."

Attendees will hear presentations from experts in the field, including Hershman and members of the global training and coaching community, who will inspire with stories of success, current implementation best practices, and creative applications of Agile principles.

Centered around prioritizing individuals over tools and processes, this year's European Global Gathering will focus on the importance of skilled, professional individuals who are empowered and respected within their organizations.

Sessions, tracks, speakers, and demonstrations will show how an empowered worker leads to a better product. Features include:

Open Space every day : Scrum and Agile work in action as attendees self-organize and develop sessions in real time.  

On-site creation of an artificial intelligence (AI) code : Xavier Detant uses Scrum principles to create an AI code from scratch.    

"Our Gathering co-chairs Iain McKenna and Michel Goldenberg have assembled an incredible group of experts to both instruct and breed inspiration for attendees in a plethora of fields from coding to business process," Hershman said. "Attendees are going to walk away from three days in Dublin with a better understanding of how to truly implement Scrum, empower their coworkers and employees and, ultimately, have a healthier bottom line, a happier customer, and a more satisfied work life."

Scrum Alliance continues to experience rapid growth in Europe: In 2016, Scrum Alliance trainers and coaches certified 24,000 individuals in Europe. About a third of the organization's overall membership is now in Europe, which is approaching North America in total market size.

Scrum Alliance hosts two Global Gatherings per year, one in North America and one in Europe. To learn more about future Global and Regional Gatherings, please visit  www.scrumalliance.org.

About Scrum Alliance

Founded in 2001, SCRUM ALLIANCE® is the largest, most established and influential professional membership and certification organization in the Agile community. SCRUM ALLIANCE® is a nonprofit association with more than 500,000 members worldwide. Its vision is to "Transform the World of Work" with a mission to guide and inspire individuals, leaders, and organizations with practices, principles, and values that create workplaces that are joyful, prosperous, and sustainable. For more information, please visit www.scrumalliance.org.

Connect with us on social media at: 

https://twitter.com/ScrumAlliance

https://www.facebook.com/scrumalliance

https://www.linkedin.com/company/scrum-alliance

https://plus.google.com/+scrumalliance/posts

https://www.youtube.com/user/scrumalliance

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/46f7b8d2-d7c8-47de-b1fe-935f0cf6d65d

Heather Leigh
Scrum Alliance
720-443-7314
hleigh@scrumalliance.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Scrum Alliance via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum